FOR IMMEDIATE RELEASE
GLOBAL CANCER TECHNOLOGY LAUNCHES THYROID CANCER RESEARCH PROGRAM TO EVALUATE GCT-007 IN DRUG-RESISTANT THYROID CANCER MODELS
Collaboration with MD Anderson investigator expands development of next-generation PI3K inhibitor into another treatment-resistant cancer indication.
SAN DIEGO, Calif. – March 9, 2026 – Global Cancer Technology (GCT), a preclinical-stage biopharmaceutical company developing novel therapies for aggressive and treatment-resistant cancers, today announced a research collaboration with Anastasios Maniakas, M.D., Ph.D., Assistant Professor of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center. The collaboration will evaluate GCT-007 in preclinical models of thyroid cancer.
Expanding Research in PI3K-Driven Thyroid Cancer
The study will examine how phosphoinositide 3-kinase (PI3K) pathway dysregulation contributes to thyroid cancer. In addition, researchers will assess the therapeutic activity of GCT-007, GCT’s next-generation PI3K inhibitor, in thyroid cancer models that may develop recurrence and treatment resistance.
The PI3K signaling pathway is one of the most frequently altered pathways in cancer. Researchers have linked it to tumor growth, disease progression, and resistance to therapy across many cancer types. Moreover, emerging evidence suggests that PI3K activation plays an important role in aggressive and recurrent forms of thyroid cancer. As a result, researchers have an opportunity to explore new targeted treatment approaches.
Scientific Rationale for GCT-007
“Activation of the PI3K pathway is a known driver of recurrence and therapeutic resistance in thyroid cancer, similar to what we observe in glioblastoma and drug-resistant breast cancer,” said Karen Newell Rogers, Ph.D., Chief Scientific Officer of Global Cancer Technology. “These shared molecular characteristics make thyroid cancer a logical and scientifically compelling extension of our GCT-007 research program. We look forward to learning whether our next-generation PI3K inhibitor may have broader applications across multiple difficult-to-treat cancers.“
Advancing Therapies for Unmet Medical Needs
John Clark, Founder and Chief Executive Officer of Global Cancer Technology, said the collaboration reflects the company’s strategy of pursuing high-impact opportunities where PI3K dysregulation contributes to poor patient outcomes.
“Our goal is to develop therapies that address cancers with significant unmet medical needs,” Clark said. “By partnering with one of the world’s leading cancer centers and an accomplished thyroid cancer investigator, we can generate important insights into the potential of GCT-007. Furthermore, this collaboration will expand our understanding of where this technology may have the greatest clinical impact.“
The study marks another milestone in GCT’s efforts to advance GCT-007 as a potential therapeutic candidate for multiple PI3K-driven cancers. Meanwhile, the company continues to raise capital to support its planned Phase I clinical trial program.
About Global Cancer Technology
Global Cancer Technology is a preclinical-stage biopharmaceutical company focused on developing novel therapies for aggressive and treatment-resistant cancers. Its lead therapeutic candidate, GCT-007, is a next-generation PI3K inhibitor that researchers are evaluating across multiple cancer indications characterized by PI3K pathway dysregulation. The company is currently preparing for a Phase I clinical trial and pursuing strategic collaborations to accelerate development.
For more information, visit www.globalcancertechnology.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of GCT-007, the outcomes of preclinical studies, future clinical development activities, and fundraising initiatives. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Therefore, there can be no assurance that GCT-007 will successfully complete development, receive regulatory approval, or achieve commercial success.
